此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Predictors of BCR After RARP for Localized Prostate Cancer: A Retrospective Analysis

Predictors of Biochemical Recurrence After Robot-Assisted Radical Prostatectomy in Patients With Localized Prostate Cancer: A Retrospective Analysis

This retrospective study aims to identify predictive factors for biochemical recurrence (BCR) in patients with localized prostate cancer who underwent robot-assisted radical prostatectomy (RARP). BCR is defined as a rise in prostate-specific antigen (PSA) levels after surgery, which may indicate residual or recurrent disease.

We will analyze clinical, imaging, and pathological data from patients treated at Fujian Medical University Affiliated First Hospital between January 2024 and May 2026. Key variables include preoperative PSA, Gleason score, pathological T stage, surgical margin status, perineural invasion, prostate volume, MRI-based parameters (e.g., Pi-RADS score, SUVmax on PSMA PET/CT), and inflammatory markers.

Using logistic regression and machine learning approaches (random forest, XGBoost, SVM), we will develop and internally validate a predictive model to estimate individual BCR risk. The goal is to improve post-surgical risk stratification, guide personalized monitoring, and support clinical decision-making regarding adjuvant therapy.

This research has received ethical approval. Data will be anonymized and handled confidentially. Findings will be disseminated to inform clinical practice and future research.

研究概览

地位

尚未招聘

研究类型

观察性的

注册 (估计的)

200

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:ZhongHua Zhu
  • 电话号码:+8618060692924
  • 邮箱:drzhuzh@163.com

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人
  • 年长者

接受健康志愿者

不

取样方法

非概率样本

研究人群

All patients with localized prostate adenocarcinoma (clinical stage T1-T2, N0M0) who underwent robot-assisted radical prostatectomy (RARP) at Fujian Medical University Affiliated First Hospital between January 2020 and May 2026. Consecutive patients meeting eligibility criteria are included. No specific sampling frame or probability sampling method is applied.

描述

Inclusion Criteria:

  • Pathologically confirmed prostate adenocarcinoma

Clinical stage localized prostate cancer (T1-T2, N0M0)

Underwent robot-assisted radical prostatectomy (RARP)

Age ≥ 18 years

Complete clinical data including preoperative PSA, Gleason score, pathological T stage, and surgical margin status

At least one postoperative PSA measurement available to determine biochemical recurrence status

Signed informed consent for surgery and data use (or ethics committee waiver of consent for retrospective analysis)

Exclusion Criteria:

  • Received neoadjuvant endocrine therapy, radiotherapy, or chemotherapy prior to surgery

Concurrent active malignancy other than non-melanoma skin cancer

Preoperative evidence of lymph node metastasis (N+), distant metastasis (M1), or clinical stage T3-T4

Missing core predictors (e.g., preoperative PSA, Gleason score, pathological T stage) or insufficient postoperative PSA data to determine BCR status

Received adjuvant radiotherapy or adjuvant endocrine therapy before biochemical recurrence was determined

Severe cardiac, hepatic, or renal dysfunction, or life expectancy < 1 year

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
RARP Cohort
Consecutive patients with localized prostate cancer who underwent robot-assisted radical prostatectomy (RARP) at Fujian Medical University Affiliated First Hospital between January 2024 and May 2026. Patients are followed postoperatively for biochemical recurrence (BCR). Clinical, imaging, and pathological data are collected to identify predictors of BCR.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Biochemical Recurrence
大体时间:From date of surgery until date of confirmed biochemical recurrence, assessed up to 76 months, from January 2020 to May 2026
Biochemical recurrence (BCR) is defined as a postoperative serum prostate-specific antigen (PSA) level of ≥0.2 ng/mL on two consecutive measurements, with the second measurement confirming the elevation. This is the primary outcome event for the study, used to distinguish patients with recurrence from those without recurrence during follow-up.
From date of surgery until date of confirmed biochemical recurrence, assessed up to 76 months, from January 2020 to May 2026

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年7月15日

初级完成 (估计的)

2026年7月20日

研究完成 (估计的)

2026年9月30日

研究注册日期

首次提交

2026年6月28日

首先提交符合 QC 标准的

2026年6月28日

首次发布 (实际的)

2026年7月6日

研究记录更新

最后更新发布 (实际的)

2026年7月6日

上次提交的符合 QC 标准的更新

2026年6月28日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

This is a single-center retrospective study, and patient data confidentiality agreements restrict sharing of individual participant data.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅